- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:36 | JOYZYME GROUP (08622): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 14:33 | JOYZYME GROUP (08622): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 26 JUNE 2026 AT 4:00 P.M. (OR AT ANY ADJOURNMENT THEREOF) | - | HKEx | ||
| JOYZYME GROUP Aktie jetzt für 0€ handeln | |||||
| 14:30 | JOYZYME GROUP (08622): (1) PROPOSED RE-ELECTION OF RETIRING DIRECTORS; (2) PROPOSED RE-APPOINTMENT OF AUDITOR; (3) PROPOSED GRANTING OF GENERAL MANDATES ... | - | HKEx | ||
| Do | JOYZYME GROUP (08622): PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF AMENDED AND RESTATED MEMORANDUM AND ARTICLES ... | 1 | HKEx | ||
| 27.04. | JOYZYME GROUP (08622): ANNUAL REPORT 2025 | - | HKEx | ||
| 30.03. | JOYZYME GROUP (08622): COMPANY INFORMATION SHEET | - | HKEx | ||
| 30.03. | JOYZYME GROUP (08622): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 30.03. | JOYZYME GROUP (08622): RESIGNATION OF NON-EXECUTIVE DIRECTOR | - | HKEx | ||
| 27.03. | JOYZYME GROUP (08622): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025 | 1 | HKEx | ||
| 17.03. | JOYZYME GROUP (08622): NOTIFICATION OF BOARD MEETING | - | HKEx | ||
| 09.02. | JOYZYME GROUP (08622): COMPANY INFORMATION SHEET | - | HKEx | ||
| 04.02. | HUAKANG BIOMED (08622): (1) CHANGE OF COMPANY NAME (2) CHANGE OF STOCK SHORT NAME (3) CHANGE OF COMPANY LOGO (4) CHANGE OF COMPANY WEBSITE | - | HKEx | ||
| 15.01. | HUAKANG BIOMED (08622): POLL RESULTS OF EXTRAORDINARY GENERAL MEETING HELD ON 15 JANUARY 2026 | - | HKEx | ||
| 23.12.25 | HUAKANG BIOMED (08622): POSTPONEMENT OF THE EXTRAORDINARY GENERAL MEETING AND CHANGE OF BOOK CLOSURE PERIOD AND RECORD DATE | - | HKEx | ||
| 22.12.25 | HUAKANG BIOMED (08622): FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON THURSDAY, 8 JANUARY 2026 AT 11:00 A.M. | - | HKEx | ||
| 22.12.25 | HUAKANG BIOMED (08622): NOTICE OF EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 22.12.25 | HUAKANG BIOMED (08622): PROPOSED CHANGE OF COMPANY NAME AND NOTICE OF EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 19.12.25 | HUAKANG BIOMED (08622): SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024 | - | HKEx | ||
| 15.12.25 | HUAKANG BIOMED (08622): VOLUNTARY ANNOUNCEMENT EXEMPTED CONTINUING CONNECTED TRANSACTION | - | HKEx | ||
| 15.12.25 | HUAKANG BIOMED (08622): COMPANY INFORMATION SHEET | - | HKEx |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 31,645 | +0,43 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Interesse der Investoren habe vor allem dem Tuberkulosetest... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,540 | +0,75 % | Bernstein reiterates Summit Therapeutics stock Underperform rating | ||
| SIONNA THERAPEUTICS | 42,820 | +0,05 % | Stifel reiterates Buy on Sionna Therapeutics stock ahead of data | ||
| RELAY THERAPEUTICS | 14,050 | +1,08 % | H.C. Wainwright raises Relay Therapeutics stock price target to $28 on trial data | ||
| NURIX THERAPEUTICS | 17,760 | +0,51 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update | Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Enabling Phase 3 DAYBreak CLL-306 bexobrutideg... ► Artikel lesen | |
| ALUMIS | 21,600 | +0,93 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 59,40 | -0,24 % | Tarsus Pharmaceuticals, Inc: Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease | - A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission - IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals... ► Artikel lesen | |
| ERASCA | 12,840 | +5,25 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| NUVALENT | 110,38 | +1,02 % | FDA accepts Nuvalent's neladalkib application with priority review | ||
| RECURSION PHARMACEUTICALS | 3,575 | +3,92 % | Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now? | ||
| ABSCI | 6,745 | +10,94 % | BTIG initiates Absci stock with buy rating on AI drug platform | ||
| TREVI THERAPEUTICS | 14,140 | -2,15 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates | Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 349,97 | -0,75 % | H.C. Wainwright reiterates Praxis Precision stock rating on patent news | ||
| CULLINAN THERAPEUTICS | 16,440 | +7,03 % | Morocco and Finland Launch Business Council in Helsinki as Tazi Makes First European Outing as CGEM President | ||
| CLEARMIND MEDICINE | 3,550 | +44,90 % | Clearmind Medicine Inc.: Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment | Vancouver, Canada, May 29, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development... ► Artikel lesen |
Das Unternehmen JOYZYME GROUP LTD kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JOYZYME GROUP LTD finden Sie auf Wallstreet Online.